AYAL Capital Advisors Ltd Buys New Position in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• AYAL Capital Advisors Ltd acquired 66,715 shares of ANI Pharmaceuticals, valued at approximately $4.47 million, making it 1.5% of their portfolio.
• ANI Pharmaceuticals reported $1.80 earnings per share for the last quarter, surpassing estimates and marking a revenue increase of 53.2% year-over-year.
• Insider transactions included the COO and CFO selling significant portions of their shares, with insiders collectively selling 405,538 shares valued at over $35 million in the past 90 days.

AYAL Capital Advisors Ltd acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 66,715 shares of the specialty pharmaceutical company's stock, valued at approximately $4,467,000. ANI Pharmaceuticals comprises 1.5% of AYAL Capital Advisors Ltd's investment portfolio, making the stock its 20th biggest holding. AYAL Capital Advisors Ltd owned approximately 0.31% of ANI Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ANIP. National Bank of Canada FI purchased a new stake in ANI Pharmaceuticals during the 1st quarter worth approximately $79,000. GAMMA Investing LLC increased its holdings in ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after purchasing an additional 881 shares during the last quarter. Rafferty Asset Management LLC purchased a new stake in ANI Pharmaceuticals during the 4th quarter worth approximately $200,000. Bridgefront Capital LLC purchased a new stake in ANI Pharmaceuticals during the 4th quarter worth approximately $204,000. Finally, Mesirow Financial Investment Management Inc. purchased a new stake in ANI Pharmaceuticals during the 1st quarter worth approximately $206,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $86.97, for a total value of $1,739,400.00. Following the completion of the transaction, the senior vice president owned 173,226 shares of the company's stock, valued at approximately $15,065,465.22. This represents a 10.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jeanne Thoma sold 21,540 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $89.15, for a total value of $1,920,291.00. Following the completion of the transaction, the director directly owned 23,405 shares of the company's stock, valued at approximately $2,086,555.75. The trade was a 47.93% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 412,830 shares of company stock valued at $36,382,434. Company insiders own 12.70% of the company's stock.

Analyst Ratings Changes

ANIP has been the topic of several research reports. Truist Financial upped their price objective on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research note on Monday, August 11th. Zacks Research upgraded ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 21st. HC Wainwright reiterated a "buy" rating and issued a $93.00 price target (up from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Finally, Guggenheim boosted their price target on ANI Pharmaceuticals from $86.00 to $114.00 and gave the company a "buy" rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $88.25.

ANI Pharmaceuticals Stock Performance

ANIP traded down $0.22 during trading on Monday, reaching $95.14. 129,044 shares of the company were exchanged, compared to its average volume of 374,139. The stock has a market cap of $2.06 billion, a P/E ratio of -123.38 and a beta of 0.63. The firm has a 50 day moving average of $76.26 and a 200 day moving average of $68.36. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $96.56.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. During the same period in the prior year, the business earned $1.02 EPS. The firm's revenue was up 53.2% on a year-over-year basis. On average, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.